David Gionco Sells 8,984 Shares of Stemline Therapeutics Inc (STML) Stock
Stemline Therapeutics Inc (NASDAQ:STML) insider David Gionco sold 8,984 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $17.43, for a total transaction of $156,591.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
David Gionco also recently made the following trade(s):
- On Wednesday, January 17th, David Gionco sold 4,250 shares of Stemline Therapeutics stock. The stock was sold at an average price of $13.43, for a total transaction of $57,077.50.
Shares of Stemline Therapeutics Inc (NASDAQ:STML) opened at $16.85 on Friday. The stock has a market cap of $485.28, a P/E ratio of -6.56 and a beta of -0.07. Stemline Therapeutics Inc has a 1-year low of $7.30 and a 1-year high of $18.00.
Several hedge funds and other institutional investors have recently made changes to their positions in STML. Alliancebernstein L.P. acquired a new stake in shares of Stemline Therapeutics during the 2nd quarter worth approximately $178,000. Teachers Advisors LLC increased its holdings in shares of Stemline Therapeutics by 1.3% during the 2nd quarter. Teachers Advisors LLC now owns 43,397 shares of the biopharmaceutical company’s stock worth $399,000 after buying an additional 541 shares during the last quarter. Nationwide Fund Advisors increased its holdings in shares of Stemline Therapeutics by 7.2% during the 2nd quarter. Nationwide Fund Advisors now owns 12,755 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 855 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Stemline Therapeutics by 18.0% during the 2nd quarter. Northern Trust Corp now owns 274,824 shares of the biopharmaceutical company’s stock worth $2,529,000 after buying an additional 41,898 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Stemline Therapeutics by 4.7% during the 2nd quarter. Vanguard Group Inc. now owns 863,768 shares of the biopharmaceutical company’s stock worth $7,946,000 after buying an additional 38,615 shares during the last quarter. Institutional investors and hedge funds own 42.52% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/david-gionco-sells-8984-shares-of-stemline-therapeutics-inc-stml-stock/1904826.html.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.